Vita, Emanuele
 Distribuzione geografica
Continente #
AS - Asia 689
NA - Nord America 654
EU - Europa 502
SA - Sud America 200
AF - Africa 23
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.071
Nazione #
US - Stati Uniti d'America 620
SG - Singapore 323
BR - Brasile 166
CN - Cina 158
IT - Italia 128
SE - Svezia 103
DE - Germania 63
VN - Vietnam 51
IN - India 43
FR - Francia 34
GB - Regno Unito 34
FI - Finlandia 26
ID - Indonesia 21
AR - Argentina 18
NL - Olanda 18
CA - Canada 16
IE - Irlanda 16
KR - Corea 16
RU - Federazione Russa 15
HK - Hong Kong 14
AT - Austria 13
MX - Messico 13
JP - Giappone 11
TR - Turchia 11
BD - Bangladesh 10
CZ - Repubblica Ceca 10
IQ - Iraq 10
PL - Polonia 10
ES - Italia 8
ZA - Sudafrica 7
EC - Ecuador 6
LT - Lituania 6
CO - Colombia 5
UA - Ucraina 5
BE - Belgio 4
CI - Costa d'Avorio 4
TN - Tunisia 4
IR - Iran 3
JO - Giordania 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
MA - Marocco 2
UZ - Uzbekistan 2
AL - Albania 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GI - Gibilterra 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
ML - Mali 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
SN - Senegal 1
UY - Uruguay 1
VE - Venezuela 1
Totale 2.071
Città #
Singapore 179
Ashburn 112
Chandler 56
New York 51
Rome 45
Hefei 39
Hyderabad 35
Los Angeles 35
Beijing 26
The Dalles 25
Ho Chi Minh City 21
Milan 20
Dallas 18
Jakarta 17
Munich 17
São Paulo 17
Cattolica 16
Dublin 16
Frankfurt am Main 16
Seoul 16
Boardman 14
Hong Kong 13
Hanoi 12
Helsinki 11
Kent 11
Santa Clara 11
Tokyo 11
Buffalo 10
Brno 9
Orem 9
Turku 9
Brooklyn 8
Düsseldorf 8
Moscow 8
Vienna 8
Boston 7
Chicago 7
San Mateo 7
Stockholm 7
Atlanta 6
Bexley 6
Bremen 6
Denver 6
Lappeenranta 6
Phoenix 6
Poplar 6
Princeton 6
Warsaw 6
Amsterdam 5
Des Moines 5
Johannesburg 5
Marseille 5
Abidjan 4
Brussels 4
Council Bluffs 4
Falkenstein 4
Goiânia 4
London 4
Madrid 4
Middlesbrough 4
North Bergen 4
Nuremberg 4
Orangeburg 4
Portsmouth 4
Quito 4
Toronto 4
Wroclaw 4
Amman 3
Ankara 3
Baghdad 3
Campinas 3
Charlotte 3
Cuiabá 3
Fairfield 3
Houston 3
Lauterbourg 3
Manaus 3
Montreal 3
Ottawa 3
Paris 3
Petrozavodsk 3
Piracicaba 3
Querétaro 3
Santo André 3
Seattle 3
Starnberg 3
Wilmington 3
Aracaju 2
Baku 2
Belo Horizonte 2
Bogotá 2
Brasília 2
Busto Arsizio 2
Bắc Ninh 2
Campo Grande 2
Can Tho 2
Chennai 2
Curitiba 2
Da Nang 2
Dhaka 2
Totale 1.177
Nome #
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 143
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study 136
From palliation to cure: PIPAC for peritoneal malignancies 122
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors 111
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 110
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer 110
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 109
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 102
Oncogene-addicted non-small-cell lung cancer: Treatment opportunities and future perspectives 102
Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery 98
Prognostic factors and long-term survival in locally advanced nsclc with pathological complete response after surgical resection following neoadjuvant therapy 95
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis 94
Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics 91
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 85
Comparative Analysis of Comprehensive Genomic Profile in Thymomas and Recurrent Thymomas Reveals Potentially Actionable Mutations for Target Therapies 84
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer 80
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) 80
Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis 79
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study 74
Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative Review 68
Surgery after induction chemo or immunotherapy for locally advanced NSCLC 65
Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma 62
Totale 2.100
Categoria #
all - tutte 8.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.775


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 1 4 10 1
2021/202272 20 0 1 14 1 1 0 8 2 2 8 15
2022/2023157 21 20 13 27 9 23 11 8 18 0 2 5
2023/2024203 3 35 9 10 8 18 26 9 2 21 21 41
2024/2025679 23 6 41 34 42 30 32 20 85 109 146 111
2025/2026966 180 78 110 259 295 44 0 0 0 0 0 0
Totale 2.100